Published in Clin Cancer Res on August 01, 1997
Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol Cell Biol (2003) 1.43
ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther (2008) 1.19
Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer (2011) 1.05
New strategy for overcoming resistance to chemotherapy of ovarian cancer. Yonago Acta Med (2013) 0.93
Toxicity patterns of cytotoxic drugs. Invest New Drugs (2003) 0.86
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecol Oncol (2008) 0.84
Oral topoisomerase 1 inhibitors in adult patients: present and future. Invest New Drugs (1999) 0.84
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. Int J Gynecol Cancer (2013) 0.81
Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493). Leuk Lymphoma (2012) 0.80
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst (1995) 4.29
Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst (2000) 3.57
Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA (2001) 3.37
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA (1988) 2.41
Prospective study of factors influencing the onset of natural menopause. J Clin Epidemiol (1998) 2.30
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Rifampicin inhibition of ribonucleic acid and protein synthesis in normal and ethylenediaminetetraacetic acid-treated Escherichia coli. J Bacteriol (1970) 2.19
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol (1997) 2.17
Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci (2001) 1.87
Serum insulin-like growth factor-I and breast cancer. Int J Cancer (2000) 1.82
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res (2001) 1.76
Risk of breast cancer and organochlorine exposure. Cancer Epidemiol Biomarkers Prev (2000) 1.70
Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1986). Ann Intern Med (1988) 1.69
Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol (2004) 1.63
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol (2003) 1.63
Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res (2001) 1.59
Serum folate, homocysteine and colorectal cancer risk in women: a nested case-control study. Br J Cancer (1999) 1.52
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol (2005) 1.50
Types of dietary fat and breast cancer: a pooled analysis of cohort studies. Int J Cancer (2001) 1.48
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res (2000) 1.33
9-(1,3-Dihydroxy-2-propoxymethyl)guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome. Ann Intern Med (1987) 1.32
Aspirin and epithelial ovarian cancer. Prev Med (2001) 1.30
Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol (1996) 1.27
Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol (1989) 1.25
Iron intake, body iron stores and colorectal cancer risk in women: a nested case-control study. Int J Cancer (1999) 1.24
Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol (1994) 1.23
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol (2006) 1.22
A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy. I. Emergence and recovery profiles. Anesth Analg (2001) 1.19
A cross-sectional study of IGF-I determinants in women. Eur J Cancer Prev (2001) 1.19
Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med (1980) 1.19
Hypericin as an inactivator of infectious viruses in blood components. Transfusion (1995) 1.19
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med (1988) 1.18
Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res (2000) 1.18
Aspirin and lung cancer in women. Br J Cancer (2002) 1.18
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res (2001) 1.18
HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Defic Syndr (1992) 1.15
Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2001) 1.14
Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother (2001) 1.14
Hydrodynamic diameters of RNA tumor viruses. Studies by laser beat frequency light scattering spectroscopy of avian myeloblastosis and Rauscher murine leukemia viruses. Biochemistry (1975) 1.14
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res (2003) 1.11
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol (1992) 1.08
Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol (1999) 1.06
HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol (1998) 1.05
Epidemiologic correlates with menstrual cycle length in middle aged women. Eur J Epidemiol (1999) 1.04
Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol (2001) 1.04
Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene (2008) 1.03
Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. Ann Intern Med (1990) 1.03
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med (1980) 1.02
Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol (1993) 1.02
Comparison of active and cancer registry-based follow-up for breast cancer in a prospective cohort study. Am J Epidemiol (1999) 1.01
Diet, smoking and anthropometric indices and postmenopausal bone fractures: a prospective study. Int J Epidemiol (2000) 0.99
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med (1985) 0.99
Serum carotenoids as biomarkers of fruit and vegetable consumption in the New York Women's Health Study. Public Health Nutr (2001) 0.99
Disposition and pharmacokinetics of phenethyl isothiocyanate and 6-phenylhexyl isothiocyanate in F344 rats. Drug Metab Dispos (1999) 0.99
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol (1996) 0.98
Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR Am J Roentgenol (1979) 0.97
Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood (1992) 0.94
Ganciclovir treatment of gastrointestinal infections caused by cytomegalovirus in patients with AIDS. Rev Infect Dis (1988) 0.93
Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol (1990) 0.90
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med (1999) 0.90
Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Cancer Res (1998) 0.90
A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation. Int J Radiat Oncol Biol Phys (1984) 0.90
Psychotropic medication use and risk of hormone-related cancers: the New York University Women's Health Study. J Public Health Med (2000) 0.89
Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study. J Clin Oncol (1993) 0.89
Therapeutic trial of interferon-gamma in patients with epidemic Kaposi's sarcoma. J Biol Response Mod (1985) 0.89
Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: a RTOG Study. Int J Radiat Oncol Biol Phys (1988) 0.88
Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet (1991) 0.88
Strategies for evaluation of enveloped virus inactivation in red cell concentrates using hypericin. Photochem Photobiol (2000) 0.88
Correcting for measurement error in the analysis of case-control data with repeated measurements of exposure. Am J Epidemiol (1997) 0.87
Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin. Lancet (1997) 0.87
Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol (1999) 0.87
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst (1992) 0.87